Q-omics provides the consensus-scored OLIG1 profile across patient tissues and cancer cell-line models. OLIG1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OLIG1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, OLIG1 RNA expression shows 11,680 significant gene co-expression associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRP, and GBM as cancer lineages where OLIG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OLIG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OLIG1 survival associations across molecular data types. OLIG1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OLIG1 RNA expression–survival associations across cancer types. High OLIG1 expression shows unfavorable associations in UVM, LUSC and STAD, but favorable associations in KICH, LGG and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for OLIG1 RNA expression.
This table summarizes OLIG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for OLIG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OLIG1 shows lower tumor expression in KIRP, KIRC, LUSC, HNSC and LUAD and higher tumor expression in PRAD. The KIRP box plot shows higher OLIG1 RNA expression in normal versus tumor tissue (log2 FC = −2.283, t-test p < 0.001).
This table shows molecular features associated with OLIG1 in patient tissues and cancer cell lines. In patient samples, OLIG1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OLIG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
